Introduction: Developing countries can improve their pharmacovigilance systems by analysing their own medication safety data.
Objective: The aims of this study were to characterize Uganda's reported adverse drug reaction (ADR) onsets in 2012-2015 that were registered on VigiBase by 31 December 2017, to document delays in international visibility and the influence of covariates on this delay from ADR onsets in 2013 + 2014, to examine data quality, and to illustrate analytical approaches for safety data, particularly for patients receiving antiretroviral therapy (ART).
Methods: International delay was defined as elapsed time from complete ADR onset date to entry date on VigiBase, with covariates examined using Cox proportional hazards regression. Simple random sampling was used to locate the paper-based ADR forms for data quality assurance. Disproportionality for signal detection focused on serious singleton ADR onsets in patients receiving ART.
Results: Uganda's VigiBase had 1018 patient entries with complete ADR onset dates: 260 in 2012, 293 in 2013, 305 in 2014 and 160 in 2015. Only 16% (154/953) of ADR onsets in 2012-2015 were in patients aged < 20 years for whom randomly sampled ADR forms were less fully completed; 87% (889/1018) comprised a singleton sign/symptom; half were serious. Median delay from ADR onset to international visibility was 11 months for ADR onsets in 2013 + 2014, and longest for healthcare professionals other than pharmacists and physicians. Disproportionality for serious ADR onsets in patients receiving ART included anaemia with zidovudine, renal impairment with tenofovir, Stevens-Johnson syndrome with nevirapine and skin rash with efavirenz.
Conclusions: Barely one ADR onset per day was registered on VigiBase from those submitted to Uganda's National Pharmacovigilance Centre during 2012-2014; only one in six was from patients aged < 20 years. Paediatric pharmacovigilance requires more emphasis in Uganda. Delays from reported ADR onset to international visibility on VigiBase need to reduce dramatically. Quality assurance revealed rectifiable data entry deficits. Signal detection performed well for patients receiving ART.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267548 | PMC |
| http://dx.doi.org/10.1007/s40290-018-0253-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of a self-screening tool and patient alert cards to help patients identify and manage severe adverse drug reactions.
Int J Clin Pharm
January 2025
Division of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, 40002, Thailand.
Background: Few studies have examined the use of self-screening tools and patient alert cards (PAC) for screening adverse drug reactions (ADRs).
Aim: To evaluate the benefits of self-screening tools and PAC for screening ADRs.
Method: A prospective study of outpatients was conducted at a tertiary care teaching hospital.
Lactic acidosis with metformin accumulation in the intensive care units of the Nord Pas de Calais region: A known serious adverse event that can be better prevented.
Therapie
December 2024
CHU Lille, University Lille, Intensive Médecine Reanimation, 59000 Lille, France.
Article Synopsis
- The study focused on identifying situations that lead to metformin-associated lactic acidosis (MALA) in ICU patients and evaluating its preventability.
- A total of 198 MALA cases were assessed, with 19.2% resulting in death; the majority of patients had acute events like dehydration or severe infections that contributed to the condition.
- The findings indicated that MALA is often preventable, highlighting the need for better physician and patient education regarding metformin use during high-risk medical situations.
Drug-induced retinal vein occlusion: a disproportionality analysis from the FDA adverse event reporting system (2004-2023).
Front Pharmacol
December 2024
Department of Ophthalmology, Hui'an County Hospital, Quanzhou, Fujian, China.
Introduction: Retinal vein occlusion (RVO) often causes irreversible visual impairment, making early prevention crucial. This study aims to identify associations between different medications and RVO and provide information for clinical practice.
Method: This study included reports of RVO from the FDA Adverse Event Reporting System (FAERS) database from the first quarter (Q1) of 2004 to the fourth quarter (Q4) of 2023.
Fbxo11 maintains mitochondrial function and prevents podocyte injury in adriamycin-induced nephropathy by mediating the ubiquitin degradation of Fosl2.
Exp Cell Res
January 2025
Department of Nephrology, General Hospital of Northern Theater Command, No.83, Wenhua Road, Shenhe District, Shenyang, Liaoning, 110016, China. Electronic address:
Mitochondrial dysfunction is a pivotal factor in the onset of podocyte damage, which is a central component in the pathogenesis of nephrotic syndrome (NS). However, the precise mechanisms underlying the changes in podocyte mitochondria remain elusive. Our study aims to clarify the potential mechanisms involved in the role of F-box protein 11 (Fbxo11) in NS, specifically concentrating on its impact on mitochondrial function.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!